JP2017523169A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523169A5
JP2017523169A5 JP2017502192A JP2017502192A JP2017523169A5 JP 2017523169 A5 JP2017523169 A5 JP 2017523169A5 JP 2017502192 A JP2017502192 A JP 2017502192A JP 2017502192 A JP2017502192 A JP 2017502192A JP 2017523169 A5 JP2017523169 A5 JP 2017523169A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
group
acceptable salt
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017502192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523169A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/041574 external-priority patent/WO2016018697A1/en
Publication of JP2017523169A publication Critical patent/JP2017523169A/ja
Publication of JP2017523169A5 publication Critical patent/JP2017523169A5/ja
Withdrawn legal-status Critical Current

Links

JP2017502192A 2014-07-28 2015-07-22 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ[3,2−d]ピリミジン、フロ[3,2−d]ピリミジン、およびピロロ[3,2−d]ピリミジン Withdrawn JP2017523169A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029896P 2014-07-28 2014-07-28
US62/029,896 2014-07-28
PCT/US2015/041574 WO2016018697A1 (en) 2014-07-28 2015-07-22 Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncitial virus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019212344A Division JP6991188B2 (ja) 2014-07-28 2019-11-25 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ[3,2-d]ピリミジン、フロ[3,2-d]ピリミジン、およびピロロ[3,2-d]ピリミジン

Publications (2)

Publication Number Publication Date
JP2017523169A JP2017523169A (ja) 2017-08-17
JP2017523169A5 true JP2017523169A5 (esLanguage) 2018-08-30

Family

ID=53765598

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017502192A Withdrawn JP2017523169A (ja) 2014-07-28 2015-07-22 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ[3,2−d]ピリミジン、フロ[3,2−d]ピリミジン、およびピロロ[3,2−d]ピリミジン
JP2019212344A Active JP6991188B2 (ja) 2014-07-28 2019-11-25 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ[3,2-d]ピリミジン、フロ[3,2-d]ピリミジン、およびピロロ[3,2-d]ピリミジン
JP2021181870A Pending JP2022010149A (ja) 2014-07-28 2021-11-08 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ[3,2-d]ピリミジン、フロ[3,2-d]ピリミジン、およびピロロ[3,2-d]ピリミジン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019212344A Active JP6991188B2 (ja) 2014-07-28 2019-11-25 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ[3,2-d]ピリミジン、フロ[3,2-d]ピリミジン、およびピロロ[3,2-d]ピリミジン
JP2021181870A Pending JP2022010149A (ja) 2014-07-28 2021-11-08 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ[3,2-d]ピリミジン、フロ[3,2-d]ピリミジン、およびピロロ[3,2-d]ピリミジン

Country Status (20)

Country Link
US (5) US9828388B2 (esLanguage)
EP (3) EP3174870B1 (esLanguage)
JP (3) JP2017523169A (esLanguage)
KR (1) KR102460181B1 (esLanguage)
CN (1) CN106573939B (esLanguage)
AR (1) AR101280A1 (esLanguage)
AU (1) AU2015298207C1 (esLanguage)
BR (1) BR112017001565A2 (esLanguage)
CA (1) CA2956571C (esLanguage)
EA (1) EA032490B1 (esLanguage)
ES (2) ES2802175T3 (esLanguage)
IL (1) IL249706A0 (esLanguage)
MX (1) MX2017001284A (esLanguage)
NZ (1) NZ727996A (esLanguage)
PL (2) PL3174870T3 (esLanguage)
PT (2) PT3693367T (esLanguage)
SG (1) SG11201700213SA (esLanguage)
SI (2) SI3174870T1 (esLanguage)
TW (1) TWI678369B (esLanguage)
WO (1) WO2016018697A1 (esLanguage)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5969471B2 (ja) 2010-07-22 2016-08-17 ギリード・サイエンシズ・インコーポレーテッド パラミクソウイルス科ウイルス感染症を治療するための方法及び化合物
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
CA2972259A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN108200760B (zh) 2015-07-22 2022-04-01 英安塔制药有限公司 作为rsv抑制剂的苯并二氮杂䓬衍生物
US20190077797A1 (en) * 2015-10-30 2019-03-14 Ozkan SARI Processes for preparing 2-dihalo ribolactones
CN110573518A (zh) * 2017-01-26 2019-12-13 尤拉·S·赞特里佐斯 被取代的双环嘧啶基化合物及其组合物和用途
JP7198811B2 (ja) * 2017-09-29 2023-01-04 エナンタ ファーマシューティカルズ インコーポレイテッド Rsv阻害剤としての組み合わせ医薬剤
MX2020005392A (es) 2017-12-07 2020-12-07 Univ Emory N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos.
CN113710276B (zh) 2019-03-18 2024-03-29 英安塔制药有限公司 苯二氮䓬衍生物作为rsv抑制剂
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CN115135383B (zh) 2020-02-18 2024-06-11 吉利德科学公司 抗病毒化合物
CN111548384B (zh) * 2020-03-29 2021-04-27 常州安蒂卫生物科技有限公司 用于抗病毒治疗的被取代的n4-羟基胞苷衍生物及其前药
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
US12162857B2 (en) 2022-04-27 2024-12-10 Enanta Pharmaceuticals, Inc. Antiviral compounds
US20250109157A1 (en) * 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5458A (en) 1848-02-22 Bench-vise
US135A (en) 1837-03-03 Jesse j
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (esLanguage) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4584369A (en) * 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
CN1968605A (zh) * 2004-06-15 2007-05-23 默克公司 作为rna依赖性rna病毒聚合酶抑制剂的c-嘌呤核苷类似物
EP1814561A4 (en) 2004-10-29 2012-12-19 Biocryst Pharm Inc THEROPUTICAL FUROPYRIMIDINES AND THIENOPYRIMIDINES
RU2470936C2 (ru) 2006-12-07 2012-12-27 Дженентек, Инк. Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
WO2008089105A2 (en) 2007-01-12 2008-07-24 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
PL2155758T3 (pl) * 2007-05-10 2013-06-28 Biocryst Pharm Inc Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
SI2268642T1 (sl) 2008-04-23 2015-05-29 Gilead Sciences, Inc. 1'-substituirani karba-nukleozidni analogi za antivirusno zdravljenje
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
ME02656B (me) 2009-09-21 2017-06-20 Gilead Sciences Inc 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje
WO2011035250A1 (en) 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
JP5969471B2 (ja) * 2010-07-22 2016-08-17 ギリード・サイエンシズ・インコーポレーテッド パラミクソウイルス科ウイルス感染症を治療するための方法及び化合物
CN102351931B (zh) * 2010-09-07 2014-01-22 河南省科学院高新技术研究中心 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之2’-氟取代之碳-核苷類似物
PH12013500311B1 (en) * 2010-09-20 2017-11-08 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
ES2701020T3 (es) * 2010-09-22 2019-02-20 Alios Biopharma Inc Nucleósidos azido y análogos nucleotídicos
CA2813783C (en) 2010-10-15 2019-01-22 Shanta Bantia Methods and compositions for inhibition of polymerase
US20130273005A1 (en) 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN103748098B (zh) * 2011-10-11 2016-06-29 弗·哈夫曼-拉罗切有限公司 用于治疗或预防呼吸道合胞病毒疾病的化合物
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
EP3210993B1 (en) 2012-03-13 2018-12-12 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
KR102172040B1 (ko) * 2012-03-21 2020-10-30 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類

Similar Documents

Publication Publication Date Title
JP2017523169A5 (esLanguage)
JP2018021051A5 (esLanguage)
JP2017525699A5 (esLanguage)
RU2018105549A (ru) Производные бензодиазепина как ингибиторы rsv
JP2016527217A5 (esLanguage)
JP2017537949A5 (esLanguage)
JP2015537020A5 (esLanguage)
JP2019505529A5 (esLanguage)
JP2014532716A5 (esLanguage)
JP2014511892A5 (esLanguage)
JP2015522650A5 (esLanguage)
CA2972014A1 (en) Fused pyrimidine compounds for the treatment of hiv
JP2015504081A5 (esLanguage)
JP2016518437A5 (esLanguage)
JP2019510034A5 (esLanguage)
JP2016537382A5 (esLanguage)
JP2016506961A5 (esLanguage)
JP2015516427A5 (esLanguage)
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
JP2019504050A5 (esLanguage)
JP2019510027A5 (esLanguage)
JP2014500296A5 (esLanguage)
JP2016513696A5 (esLanguage)
JP2017517512A5 (esLanguage)
SI2738156T1 (en) TETRACYCLINE COMPOSITE SUBSTITUTED WITH 9-AMINOMETHYL